European Medicines Agency Approves Positive Opinion on Omeros' Pediatric Investigation Plan for OMS302

Omeros Corporation (NASDAQ: OMER ) today announced that the European Medicines Agency (EMA) approved a positive opinion issued by the European Pediatrics Committee (PDCO) agreeing to the Company's Pediatric Investigation Plan (PIP) for OMS302. EMA's approval of PDCO's positive opinion is a prerequisite for submission of the OMS302 Marketing